Alle Storys
Folgen
Keine Story von Oxygen Biotherapeutics Inc. mehr verpassen.

Oxygen Biotherapeutics Inc.

EANS-News: Oxygen Biotherapeutics Inc.
Now Marketing New Formulation of Dermacyte Oxygen Concentrate

Durham, NC (euro adhoc) -

  Corporate news transmitted by euro adhoc. The issuer/originator is solely
  responsible for the content of this announcement.
Company Information/Marketing/New Products/Biotechnology
Press Release
Oxygen Biotherapeutics Inc.:
Oxygen Biotherapeutics Now Marketing New Formulation of Dermacyte 
Oxygen Concentrate
DURHAM, NC —Oxygen Biotherapeutics, Inc. (NASDAQ: OXBT) today 
announced that the company has begun distribution for its newly 
formulated Dermacyte Oxygen Concentrate for the beauty and skin care 
market. The over-the-counter product is a scientifically designed 
perfluorocarbon concentrate designed to enhance oxygen delivery to 
skin. As of later this week, retail orders also can be placed on the 
Dermacyte secure website at www.BuyDermacyte.com.
"Inventory of Dermacyte sold out quickly last fall when it was 
originally introduced in a market test designed to gauge customer 
interest and response," said Chris Stern, company chairman and CEO. 
"The feedback we received from customers was quite positive. We´ve 
improved the Dermacyte concentrate to be smoother and more effective.
Therefore, we believe that our new cosmetic line has the potential to
be a significant financial contributor to our company."
Dermacyte Oxygen Concentrate is the first product in a broad and 
diverse cosmetic line currently under development.  It uses the 
company´s patented Oxycyte technology, an oxygen carrier 
scientifically designed to enhance oxygen delivery to tissues such as
skin. Some potential benefits of increased oxygenation to the skin 
include a decrease in the appearance of fine lines, wrinkles and 
dryness.
About Oxygen Biotherapeutics, Inc.
Oxygen Biotherapeutics, Inc. is dedicated to commercializing 
innovative pharmaceuticals and medical devices in the field of oxygen
therapeutics and Defense Medicine. The company has developed a 
perfluorocarbon (PFC) therapeutic oxygen carrier and liquid 
ventilation product (Oxycyte) and has out-licensed an implantable 
glucose sensor. These products are based upon core technologies that 
include biomedical applications for PFCs as well as medical and 
industrial applications for biosensors. Each of the product 
candidates is designed with advantages over currently marketed 
products in major markets including traumatic brain injury, sickle 
cell crisis, trauma, wound care, decompression sickness, acute 
respiratory distress syndrome, stroke, myocardial infarction, 
surgery, diabetes wounds and ulcers, and cosmetic applications which 
are being marketed under the Dermacyte name. More information is 
available at www.oxybiomed.com.
Caution Regarding Forward-Looking Statements.
This news release contains certain forward-looking statements by the 
company that involve risks and uncertainties and reflect the 
company's judgment as of the date of this release. These statements 
include those referring to the plans for the expansion of the 
Dermacyte product line and the timing of the introduction of those 
new products. Matters beyond the company´s control could lead to 
delays in the in the new product introductions and customer 
acceptance of these new products. Furthermore, there can be no 
assurance that such plans will lead to meaningful sales of Dermacyte 
or generate any revenue for the company. The company disclaims any 
intent or obligation to update these forward-looking statements 
beyond the date of this release. This caution is made under the safe 
harbor provisions of the Private Securities Litigation Reform Act of 
1995.
DURHAM, NC  — March 29, 2010
Links
Homepage: www.oxybiomed.com/
Dermacyte: http://www.buydermacyte.com
end of announcement                               euro adhoc

Further inquiry note:

Ellen Corliss
Oxygen Biotherapeutics, Inc.
2530 Meridian Pkwy, 3rd floor
Durham, NC 27713
Direct Telephone: +1 919 806 4405
Direct Fax: +1 919 806 4417
Email: e.corliss@oxybiomed.com

Branche: Biotechnology
ISIN: US69207P2092
WKN: A0YD9Z
Börsen: New York / Nasdaq